Famciclovir
From Wikipedia, the free encyclopedia
Famciclovir
|
|
Systematic (IUPAC) name | |
[2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)-butyl] acetate | |
Identifiers | |
CAS number | 104227-87-4 |
ATC code | J05AB09 S01AD07 |
PubChem | 3324 |
DrugBank | APRD00600 |
Chemical data | |
Formula | C14H19N5O4 |
Mol. weight | 321.332 g/mol |
Physical data | |
Melt. point | 103 °C (217 °F) |
Pharmacokinetic data | |
Bioavailability | 75–77% |
Protein binding | 20-25% |
Metabolism | Hepatic, circulation, intestinal wall (to penciclovir) |
Half life | 2–2.3 hours |
Excretion | Renal, faecal |
Therapeutic considerations | |
Pregnancy cat. | |
Legal status |
S4 (Au), POM (UK), ℞-only (U.S.) |
Routes | Oral |
Famciclovir (INN) (IPA: [pɛnˈsaɪklovir]) is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir (Novartis).
In Korean it is sold under the brand name 팜시바 with the generic name of 팜시클바.
[edit] See also
Antivirals (primarily J05A, also S01AD and D06BB) edit | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|